A5073042611- Clostridium difficile and Clostridium perfringens research
- Nosocomial Infections in ICU
- Gut microbiota and health
- Microscopic Colitis
- Antibiotic Use and Resistance
- Gastrointestinal motility and disorders
- Antibiotics Pharmacokinetics and Efficacy
- Viral gastroenteritis research and epidemiology
- Antifungal resistance and susceptibility
- Botulinum Toxin and Related Neurological Disorders
- Mycobacterium research and diagnosis
- Antibiotic Resistance in Bacteria
- Health Systems, Economic Evaluations, Quality of Life
- Infection Control in Healthcare
- Complementary and Alternative Medicine Studies
- Herbal Medicine Research Studies
- Pneumonia and Respiratory Infections
- Advanced Chemical Sensor Technologies
- Neutropenia and Cancer Infections
- Healthcare Systems and Technology
- Streptococcal Infections and Treatments
- Biosensors and Analytical Detection
- Helicobacter pylori-related gastroenterology studies
- Drug Transport and Resistance Mechanisms
- Antimicrobial Resistance in Staphylococcus
University of Houston
2020-2025
Importance Recurrent Clostridioides difficile infection (CDI) is a debilitating disease leading to poor health-related quality of life (HRQOL), loss productivity, anxiety, and depression. The potential association treatment with HRQOL has not been well evaluated. Objectives To explore the SER-109 compared placebo on in patients recurrent CDI up week 8. Design, Setting, Participants This study was secondary analysis randomized, double-blind, placebo-controlled trial that took place at 56...
We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE).
Antimicrobial resistance is emerging in clinical strains of
This study was the first human validation of gram-positive bacterial DNA polymerase IIIC target in patients with Clostridioides difficile infection. The primary objectives were to assess clinical cure rates and adverse events (AEs). Secondary evaluate plasma/fecal pharmacokinetics, microbiologic eradication, microbiome bile acid effects, sustained (SCC) ibezapolstat.This single-arm, open-label, phase 2a enrolled adults C. infection at 4 US centers. Patients received ibezapolstat 450 mg...
Fulminant Clostridioides difficile infection (FCDI) is associated with a 30%-40% mortality rate. Guideline definitions for FCDI severity classification include ileus, megacolon, shock, or hypotension. However, no hypotension definition provided, making application of the challenging. The objective this study was to assess optimal criteria. This multicenter cohort involving 1172 hospitalized patients diagnosed C (CDI) from 2015 2022 (Houston cohort). Patients were assessed composite endpoint...
Omadacycline, an aminomethylcycline tetracycline, has a low propensity to cause Clostridioides difficile infection (CDI) in clinical trials. Omadacycline exhibited reduced bactericidal effect compared with vancomycin on key microorganisms implicated bile acid homeostasis and short-chain fatty acids (SCFAs), components of CDI pathogenesis. The purpose this study was assess SCFA changes stool samples from healthy volunteers given omadacycline or vancomycin. Stool were collected daily 16...
Abstract Background Ibezapolstat (IBZ) is Gram-positive selective spectrum antibiotic that inhibits the bacterial DNA polymerase IIIC currently in clinical trial development for treatment of C. difficile infection (CDI) adults. In open-label, non-comparative, phase 2a study, 10 IBZ-treated CDI patients experienced cure. The purpose 2b study was to assess safety, efficacy, and microbiome change IBZ versus vancomycin (VAN). Methods Phase (ClinicalTrials.gov, number NCT04247542) a randomized,...
Abstract Background Omadacycline (OMC), an aminomethylcycline antibiotic, has potent in vitro activity against C. difficile (CD) and been associated with a low propensity to cause CD infection when used treat other infections. A recent phase 1 study of oral OMC demonstrated its protective gut microbiome profile, despite achieving high fecal concentrations, compared vancomycin healthy subjects. This aimed investigate the pharmacokinetics changes intravenous (IV) following administration...
Abstract Background Due to detection of Clostridioides difficile colonization, many hospitals changed from a PCR-based CDI diagnostic two-step using GDH/EIA assay. How this change affected the ecology C. strains or patient outcomes is unknown. The purpose study was assess differences in strain and after CDI-diagnostic Methods Stool samples considered positive by institutional policy were collected university-affiliated quaternary care hospital associated community 2016-21. cultured for...
ABSTRACT Ibezapolstat (IBZ) is a competitive inhibitor of the bacterial Pol IIIC enzyme in clinical development for treatment Clostridioides difficile infection (CDI). Previous studies demonstrated that IBZ carries favorable microbiome diversity profile compared to vancomycin (VAN). However, head-to-head comparisons with other CDI antibiotics have not been done. The purpose this study was compare changes associated clinically used antibiotics. Groups germ-free (GF) mice received fecal...
This study developed and validated a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify omadacycline its epimerization in stool facilitate microbiome studies. Omadacycline was extracted methanol-water-ethylenediaminetetraacetic acid (ETDA) solvent containing deuterated as internal standard, followed by dilution. In an optimal gradient elution mode, C4 epimer were separated within 5 min on reversed-phase C18 column. The showed broad working range of 0.1–200 ng/ml...
Clostridioides difficile infection (CDI) is a common healthcare-associated with limited treatment options. Omadacycline, an aminomethylcycline tetracycline, has potent in vitro activity against C and low propensity to cause CDI clinical trials. We aimed assess fecal pharmacokinetics gut microbiome effects of oral omadacycline compared vancomycin healthy adults.
Clostridioides difficile infection (CDI) is associated with high recurrence rates impacting health-related quality of life (HrQOL). However, patient-reported data are lacking particularly in the outpatient setting. We assessed changes HrQOL over time patients treated bezlotoxumab at US infusion centers and determined clinical factors changes.The survey was conducted adult CDI, who received 25 centers. The adapted from Cdiff32 instrument to assess anxiety-related completed on day (baseline)...
Abstract Background Ibezapolstat (IBZ) is a competitive inhibitor of the bacterial Pol IIIC enzyme in clinical development for treatment Clostridioides difficile infection (CDI). Previous studies demonstrated IBZ carries favorable microbiome diversity profile compared to vancomycin (VAN). However, head-to-head comparisons with other CDI antibiotics have not been done. The purpose this study was compare changes associated clinically used antibiotics. Methods Groups germ-free (GF) mice...
species lacking toxin genes (non-toxigenic
Patients with invasive candidiasis (IC) have complex medical and infectious disease problems that often require continued care after discharge. This study aimed to assess echinocandin use at hospital discharge develop a transition of (TOC) model facilitate for patients IC. was mixed method design used epidemiologic assessment better understand TOC. Using grounded theory methodology focused on given echinocandins during their last day hospitalization, TOC IC, the [I Can] developed barriers. A...
Abstract Background Fulminant Clostridioides difficile infection (FCDI) is associated with high rates of mortality and morbidity; however, risk factors for FCDI are poorly understood. The objective this study was to identify clinical microbiological predictive FCDI. Methods This a multicenter cohort involving adult hospitalized patients diagnosed an incident case CDI (2015-22). Leftover stool samples were collected ribotyping determination binary toxin presence (CDT; assumed in ribotypes...
Abstract Background Omadacycline is an aminomethylcycline tetracycline with potent in vitro activity against C. difficile (CD) and a low propensity for CD infection (CDI) clinical trials. In addition to activity, ideal properties of anti-CDI antibiotics include favorable effects on bile acids short-chain fatty (SCFA). The aim this study was compare acid SCFA changes healthy volunteers given oral omadacycline versus vancomycin. Methods This phase 1 volunteer 16 adults randomized 10-day course...
Abstract Background Numerous number of studies have found a positive correlation between delayed appropriate antibiotic therapy and negative clinical outcomes (NCO) in Gram-negative bacterial infections (GNBI). The combination meropenem with vaborbactam (MVB) received Food Drug Administration approval for the treatment complicated urinary tract acute pyelonephritis caused by susceptible organisms August 2017. We sought to determine impact MVB on NCO among patients GNBI. Methods Multi-center,...
Abstract Background Invasive candidiasis (IC) is a common healthcare-associated infection. Rates of IC caused by drug-resistant Candida spp., designated the CDC as serious threat, are increasing, and auris alone was recently added an urgent threat. Echinocandins guideline-preferred for treatment invasive due to in vitro potency, favorable toxicity profile, convenient dosing. The purpose this study perform pharmacoepidemiologic analysis on patterns echinocandin use at large, quaternary care...